Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avibactam/aztreonam - Allergan/AstraZeneca/Pfizer

Drug Profile

Avibactam/aztreonam - Allergan/AstraZeneca/Pfizer

Alternative Names: ATM-AVI; Aztreonam-avibactam; PF-06947387

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Biomedical Advanced Research and Development Authority; Innovative Medicines Initiative; Pfizer
  • Class Amides; Antibacterials; Heterocyclic bicyclo compounds; Monobactams; Small molecules; Sulfates
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gram-negative infections
  • Phase II Intra-abdominal infections

Most Recent Events

  • 11 Nov 2019 Avibactam/aztreonam - Allergan/AstraZeneca receives Qualified Infectious Disease Product status for Intra-abdominal infections (Complicated) in USA
  • 11 Nov 2019 Avibactam/aztreonam - Allergan/AstraZeneca receives Qualified Infectious Disease Product status for Nosocomial infections in USA
  • 11 Nov 2019 Avibactam/aztreonam - Allergan/AstraZeneca receives Qualified Infectious Disease Product status for Urinary tract infections (Complicated) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top